4-chloro-6,7-dimethoxyquinoline Chemical Properties

Melting point:

132.0 to 136.0 °C

Boiling point:

325.2±37.0 °C(Predicted)

Density 

1.265±0.06 g/cm3(Predicted)

storage temp. 

Keep in dark place,Sealed in dry,Room Temperature

solubility 

DMSO (Slightly), Methanol (Slightly)

form 

Solid

pka

3.95±0.30(Predicted)

color 

Pale Brown to Light Brown

InChI

InChI=1S/C11H10ClNO2/c1-14-10-5-7-8(12)3-4-13-9(7)6-11(10)15-2/h3-6H,1-2H3

InChIKey

WRVHQEYBCDPZEU-UHFFFAOYSA-N

SMILES

N1C2C(=CC(OC)=C(OC)C=2)C(Cl)=CC=1

CAS DataBase Reference

35654-56-9(CAS DataBase Reference)

Safety Information

Hazard Codes 

T

Risk Statements 

25

Safety Statements 

45-24/25

RIDADR 

UN2811

HazardClass 

IRRITANT

HS Code 

29334900

4-chloro-6,7-dimethoxyquinoline Usage And Synthesis

Chemical Properties

Light brown powder

Uses

4-Chloro-6,7-dimethoxyquinoline, can be used as an intermediate for the synthesis of various pharmaceutical and biologically active compounds. It is used for the preparation of Tivozanib (T447205), and Cabozantinib (C051500), acting as anticancer agents.

Application

4-chloro-6,7-dimethoxy-quinoline can be rich for Buddhist nun with for Wo Zhani medicine as preparing antitumor drug card The key intermediate of thing molecule synthesis.

Synthesis

With 3,4-dimethoxyaniline is raw material, obtains aniline compound through nitrification, iron powder reducing, then with Ethyl chloroformate, in Feldalat NM condition cyclization, prepares 4-hydroxyquinoline compounds, after through three Chlorethoxyfos chloro obtains 4-chloro-6,7-dimethoxy-quinoline.

References

[1] Patent: WO2013/180949, 2013, A1. Location in patent: Paragraph 0170
[2] Heterocycles, 2016, vol. 92, # 10, p. 1882 - 1887
[3] Patent: WO2005/121125, 2005, A1. Location in patent: Page/Page column 41-42
[4] Patent: WO2008/48375, 2008, A1. Location in patent: Page/Page column 49
[5] Journal of the American Chemical Society, 1946, vol. 68, p. 1264

4-chloro-6,7-dimethoxyquinoline(35654-56-9)Related Product Information

• Cyclopropanecarboxylic acid, 1-[[(2-fluorophenyl)amino]carbonyl]-
• Cabozantinib impurity 1DYH
• 1,1-Cyclopropanedicarboxamide, N,N'-bis[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-
• Cabozantinib Malate
• Cyclopropanecarboxylic acid, 1-[(phenylaMino)carbonyl]-
• Quinoline, 6,7-dimethoxy-4-(4-nitrophenoxy)-
• 1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-phenyl-
• Cyclopropanecarboxylic acid, 1-[[[4-[[7-methoxy-6-(sulfooxy)-4-quinolinyl]oxy]phenyl]amino]carbonyl]-
• 1-(4-Fluorophenylcarbamoyl)cyclopropanecarboxylic acid
• Cabozantinib impurity DX2
• Cabozantinib Impurity EXA
• N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide
• Cabozantinib Impurity 5
• 4-Aminoveratrole
• 4-Amino-2-Chloro-6,7-Dimethoxyquinoline
• 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE
• ethyl 4-chloro-5,8-dimethoxyquinoline-3-carboxylate
• 4-CHLORO-7,8-DIMETHOXYQUINOLINE